Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aung Naing

Showing results (361-370 of 376) with videos related to

Pageof 38
Sort By:
Frontiers in Medicine|June 18, 2025
Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitisMahnoor Mir, Felipe Soto, Pedro Antonio Amezcua Gomez, et al.
Cancers|July 8, 2020
IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive BiomarkersHesham M Amin, Ajaykumar C Morani, Najat C Daw, et al.
Frontiers in Medicine|July 11, 2025
Correction: Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitisMahnoor Mir, Felipe Soto, Pedro Antonio Amezcua Gomez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJulie R Brahmer, Christina Lacchetti, Bryan J Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline UpdateBryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.
Cell Reports. Medicine|May 21, 2026
Biomarker study of pembrolizumab in patients with advanced rare cancersAung Naing, Xiqi Li, Qi Wang, et al.
Cancer|April 22, 2022
Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort studyAjay Sheshadri, Alberto A Goizueta, Vickie R Shannon, et al.
Cancer Immunology Research|October 30, 2019
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal ResponsesJames W Welsh, Chad Tang, Patricia de Groot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO GuidelineBianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.
Pageof 38

Showing results (361-370 of 376) with videos related to

Sort By:
Pageof 38
Frontiers in Medicine|June 18, 2025
Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitisMahnoor Mir, Felipe Soto, Pedro Antonio Amezcua Gomez, et al.
Cancers|July 8, 2020
IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive BiomarkersHesham M Amin, Ajaykumar C Morani, Najat C Daw, et al.
Frontiers in Medicine|July 11, 2025
Correction: Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitisMahnoor Mir, Felipe Soto, Pedro Antonio Amezcua Gomez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJulie R Brahmer, Christina Lacchetti, Bryan J Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline UpdateBryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.
Cell Reports. Medicine|May 21, 2026
Biomarker study of pembrolizumab in patients with advanced rare cancersAung Naing, Xiqi Li, Qi Wang, et al.
Cancer|April 22, 2022
Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort studyAjay Sheshadri, Alberto A Goizueta, Vickie R Shannon, et al.
Cancer Immunology Research|October 30, 2019
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal ResponsesJames W Welsh, Chad Tang, Patricia de Groot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO GuidelineBianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.
Pageof 38